1xbet 보너스 코드 UCB Japan Co., Ltd.
1xbet 보너스 코드., Ltd.

UCB Japan Co., Ltd. (headquarters: Shinjuku-ku, Tokyo; president: Kanako Kikuchi; hereafter referred to as "UCB Japan"; when referring to the global UCB group, "UCB") and 1xbet 보너스 코드., Ltd. (headquarters: Tokyo; president and representative director: Tatsuo Higuchi; hereafter referred to as Otsuka Pharmaceutical) announced today that the co-development and co-promotion agreement for "E Keppra^®(levetiracetam)" in Japan will not be renewed, upon 1xbet 보너스 코드 term of 1xbet 보너스 코드 contract in September 2020. 1xbet 보너스 코드 two companies will work toge1xbet 보너스 코드r to transfer 1xbet 보너스 코드 development, sales, distribution, promotion and o1xbet 보너스 코드r support activities for E Keppra^®to UCB Japan. UCB Japan will assume sole responsibility for 1xbet 보너스 코드se activities after 1xbet 보너스 코드 conclusion of 1xbet 보너스 코드 contract.

Further, and in accordance with the above-mentioned June 2008 contract, 1xbet 보너스 코드 will continue to receive royalties from UCB for a fixed period. There will be no changes in the global agreement between UCB and 1xbet 보너스 코드 for Neupro^®.

UCB and 1xbet 보너스 코드 have worked together successfully to provide value to patients suffering from epilepsy in Japan. Over the course of the contract, hundreds of thousands of patients have benefitted from E Keppra^®and the programs UCB and 1xbet 보너스 코드 have supported. UCB and 1xbet 보너스 코드 will work closely to smoothly implement the transfer of E Keppra^®, and 1xbet 보너스 코드re will be no change in availability of E Keppra^®in 1xbet 보너스 코드 Japan market. 1xbet 보너스 코드 companies remain committed to contributing to healthcare by providing drugs that meet 1xbet 보너스 코드 needs of patients and healthcare professionals.

About E Keppra^®

Developed by UCB S.A. of Belgium in 1xbet 보너스 코드 early 1980s, E Keppra^®is a centrally acting anti-epileptic 1xbet 보너스 코드rapy with a mechanism of action that differs from that of any conventional anti-epileptic drug. Marketed outside of Japan under 1xbet 보너스 코드 brand name Keppra^®, the product has accumulated six million patient years of use worldwide. In Japan, it has been used as adjunctive therapy with other anti-epileptic drugs for partial-onset seizures in adult patients since September 2010 through a co-development/co-commercialization alliance between 1xbet 보너스 코드 and UCB Japan. As a result of this co-development, further indications for monotherapy for partial-onset seizures, adjunctive therapy with other anti-epileptic drugs for generalized tonic-clonic seizures, and children aged 4 years and older were added. Additional formulations, including dry syrup and I.V. infusions, have also become available.

Formulations currently available in Japan are:
E Keppra^®Tablets 250mg
E Keppra^®Tablets 500mg
E Keppra^®Dry syrup 50%
E Keppra^®for I.V. infusion 500mg